Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models
- PMID: 12915382
- DOI: 10.1152/ajprenal.00191.2002
Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models
Abstract
Tubulointerstitial fibrosis is a hallmark feature of chronic renal injury. Specific therapies to control the progression of renal fibrosis toward end-stage renal failure are limited. Previous studies have demonstrated that expression of endogenous bone morphogenic protein-7 (BMP-7) is reduced in the kidneys of several inducible mouse models of acute and chronic renal disease and that administration of exogenous recombinant human BMP-7 (rhBMP-7) has a beneficial effect on kidney function. Here we report that treatment with rhBMP-7 leads to improved renal function, histology, and survival in mice deficient in the alpha3-chain of type IV collagen and MRL/MpJlpr/lpr lupus mice, two genetic models for chronic renal injury and fibrosis. Such therapeutic benefit is also associated with a significant decrease in the expression of profibrotic molecules, such as type I collagen and fibronectin, in renal fibroblasts. Additionally, rhBMP-7 induces expression of active matrix metalloproteinase-2, which is potentially important for removal of fibrotic matrix. Collectively, these studies provide further evidence for rhBMP-7 as an important bone-associated protein with protective function against renal pathology.
Similar articles
-
BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury.Nat Med. 2003 Jul;9(7):964-8. doi: 10.1038/nm888. Nat Med. 2003. PMID: 12808448
-
The bone morphogenetic proteins (BMPs). Their role in renal fibrosis and renal function.J Nephrol. 2003 Mar-Apr;16(2):179-85. J Nephrol. 2003. PMID: 12768064 Review.
-
Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors.Diabetes. 2007 Jul;56(7):1825-33. doi: 10.2337/db06-1226. Epub 2007 Apr 24. Diabetes. 2007. PMID: 17456853
-
Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice.Kidney Int. 2006 Jul;70(1):121-9. doi: 10.1038/sj.ki.5001521. Epub 2006 May 24. Kidney Int. 2006. PMID: 16723981
-
Prevention of progressive fibrosis in chronic renal diseases: antifibrotic agents.J Nephrol. 2004 Jul-Aug;17(4):496-503. J Nephrol. 2004. PMID: 15372410 Review.
Cited by
-
Twisted gastrulation, a BMP antagonist, exacerbates podocyte injury.PLoS One. 2014 Feb 25;9(2):e89135. doi: 10.1371/journal.pone.0089135. eCollection 2014. PLoS One. 2014. PMID: 24586548 Free PMC article.
-
Tet3-mediated hydroxymethylation of epigenetically silenced genes contributes to bone morphogenic protein 7-induced reversal of kidney fibrosis.J Am Soc Nephrol. 2014 May;25(5):905-12. doi: 10.1681/ASN.2013070723. Epub 2014 Jan 30. J Am Soc Nephrol. 2014. PMID: 24480825 Free PMC article.
-
Bone morphogenetic protein 7 alleviates paraquat-induced pulmonary fibrosis via TGF-β1/Erk1/2 pathway.Int J Clin Exp Pathol. 2017 Aug 1;10(8):8503-8509. eCollection 2017. Int J Clin Exp Pathol. 2017. PMID: 31966703 Free PMC article.
-
Emerging therapies for chronic kidney disease: what is their role?Nat Rev Nephrol. 2009 Jul;5(7):375-83. doi: 10.1038/nrneph.2009.76. Epub 2009 May 19. Nat Rev Nephrol. 2009. PMID: 19455178 Review.
-
Alport syndrome--insights from basic and clinical research.Nat Rev Nephrol. 2013 Mar;9(3):170-8. doi: 10.1038/nrneph.2012.259. Epub 2012 Nov 20. Nat Rev Nephrol. 2013. PMID: 23165304 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
